文献速递头颈与中枢神经肿瘤

鼻咽癌未受累颈部选择性上颈照射对比全颈照射:一项开放标签、非劣效性、多中心、随机3期试验

Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial.
PubMed 文献 · Lancet Oncol · 2022-02-28

该开放标签、非劣效性、多中心、随机3期试验在三个中国医疗中心纳入446例N0-N1鼻咽癌患者,1:1随机接受选择性上颈照射(UNI,n=224)或全颈照射(WNI,n=222)。中位随访53个月,3年区域无复发生存率UNI组97.7% vs WNI组96.3%,差异-1.4%(95%CI -4.6至1.8),非劣效性P<0.0001;UNI组晚期毒性发生率低于WNI组。

要点

  • UNI组3年区域无复发生存率97.7%,WNI组96.3%,差异-1.4%(95%CI -4.6至1.8),非劣效性P<0.0001。
  • UNI组晚期甲状腺功能减退、皮肤毒性、吞咽困难、颈部组织损伤发生率均低于WNI组。
  • UNI组与WNI组急性放射性毒性相似,治疗期间无患者死亡。

核心结论

  • 在N0-N1鼻咽癌患者中,选择性上颈照射(UNI)与标准全颈照射(WNI)相比提供相似的区域控制,且放射性毒性更少。

研究设计与样本

  • 开放标签、非劣效性、随机、对照、3期试验,在三个中国医疗中心进行。
  • 纳入18-65岁、未经治疗、非角化型、无远处转移(M0)、N0-N1期(根据UICC-AJCC TNM分期第七版)、Karnofsky体能状态评分70或以上的鼻咽癌患者。
  • 2016年1月22日至2018年5月23日,从469例筛查患者中随机分配446例至UNI组(n=224)或WNI组(n=222),1:1随机,按治疗中心和淋巴结状态分层。
  • 放疗剂量:原发肿瘤体积和肿大咽后淋巴结70 Gy,受累颈部淋巴结66-70 Gy,高危靶区60-62 Gy,低危靶区54-56 Gy,分30-33次,每周5次。
  • II-IVA期患者推荐接受联合静脉顺铂为基础的化疗(诱导化疗后同步放化疗或单独同步放化疗)。

主要发现

  • 中位随访53个月(IQR 46-59)。
  • 3年区域无复发生存率UNI组97.7%(95%CI 95.7-99.7)vs WNI组96.3%(95%CI 93.8-98.8),差异-1.4%(95%CI -4.6至1.8),非劣效性P<0.0001。
  • 晚期毒性发生率UNI组低于WNI组:任何级别甲状腺功能减退UNI组66/222(30%)vs WNI组87/221(39%);皮肤毒性UNI组32/222(14%)vs WNI组55/221(25%);吞咽困难UNI组38/222(17%)vs WNI组71/221(32%);颈部组织损伤UNI组50/222(23%)vs WNI组88/221(40%)。
  • 急性放射性毒性两组相似;治疗期间无患者死亡;治疗后WNI组1例患者死于非癌症原因(皮肌炎)。

关键数值与推荐

  • 非劣效性界值:3年区域无复发生存率差异的95%CI上限在8%以内。
  • 3年区域无复发生存率UNI组97.7%(95%CI 95.7-99.7)vs WNI组96.3%(95%CI 93.8-98.8),差异-1.4%(95%CI -4.6至1.8),非劣效性P<0.0001。

临床怎么用

  • 对于N0-N1鼻咽癌患者,选择性上颈照射(UNI)可提供与全颈照射(WNI)相似的区域控制,且放射性毒性更少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this trial was to address whether elective ipsilateral upper-neck irradiation (UNI) sparing the uninvolved lower neck provides similar regional relapse-free survival compared with standard whole-neck irradiation (WNI) in patients with nasopharyngeal carcinoma. METHODS: This open-label, non-inferiority, randomised, controlled, phase 3 trial was done at three Chinese medical centres. Patients aged 18-65 years with untreated, non-keratinising, non-distant metastatic (M0) nasopharyngeal carcinoma; with N0-N1 disease (according to International Union Against Cancer-American Joint Committee on Cancer TNM classification, seventh edition); and a Karnofsky performance status score of 70 or higher were randomly assigned (1:1) to receive elective UNI or WNI of the uninvolved neck. Total radiation doses of 70 Gy (for the primary tumour volume and the enlarged retropharyngeal nodes), 66-70 Gy (for the involved cervical lymph nodes), 60-62 Gy (for the high-risk target volume), and 54-56 Gy (for the low-risk target volume) were administered in 30-33 fractions, five fractions per week. Patients with stage II-IVA disease were recommended to receive combined intravenous cisplatin-based chemotherapy (either induction chemotherapy followed by concurrent chemoradiotherapy or concurrent chemoradiotherapy alone). Randomisation was done centrally by the Clinical Trials Centre of Sun Yat-sen University Cancer Centre by means of a computer-generated random number code with a block size of four. Patients were stratified according to treatment centre and nodal status. Investigators and patients were not masked to treatment allocation. The primary endpoint was regional relapse-free survival in the intention-to-treat population. Non-inferiority was indicated if the upper limit of the 95% CI of the difference in 3-year regional relapse-free survival between the UNI and WNI groups was within 8%. Adverse events were analysed in the safety population (defined as all patients who commenced the randomly assigned treatment). This study is registered with ClinicalTrials.gov, NCT02642107, and is closed. FINDINGS: Between Jan 22, 2016, and May 23, 2018, 446 patients from 469 screened were randomly assigned to receive UNI (n=224) or WNI (n=222). Median follow-up was 53 months (IQR 46-59). 3-year regional relapse-free survival was similar in the UNI and WNI groups (97·7% [95% CI 95·7-99·7] in the UNI group vs 96·3% [93·8-98·8] in the WNI group; difference -1·4% [95% CI -4·6 to 1·8]; pnon-inferiority<0·0001). Although acute radiation-related toxic effects were similar between the groups, the incidence of late toxicity was lower in the UNI group than in the WNI group, including any-grade hypothyroidism (66 [30%] of 222 patients vs 87 [39%] of 221), skin toxicity (32 [14%] vs 55 [25%]), dysphagia (38 [17%] vs 71 [32%]), and neck tissue damage (50 [23%] vs 88 [40%]). No patients died during treatment. After treatment, one patient in the WNI group died from a non-cancer-related cause (dermatomyositis). INTERPRETATION: Elective UNI of the uninvolved neck provides similar regional control and results in less radiation toxicity compared with standard WNI in patients with N0-N1 nasopharyngeal carcinoma. FUNDING: Sun Yat-sen University Clinical Research 5010 Program, the Natural Science Foundation of Guangdong Province, and the Overseas Expertise Introduction Project for Discipline Innovation. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tang LL, Huang CL, Zhang N, et al. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022. PMID: 35240053. doi:10.1016/S1470-2045(22)00058-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。